logo

For the Inventor, By the Inventor

Seattle, WA, United States of America

Bruce A Mosley

This inventor holds 19 USPTO granted patents, primarily in Interleukin Receptors. Top assignee: Immunex Corporation. Active years: 1994-2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bruce A Mosley. Retrieved from https://idiyas.com/inventor/bruce-a-mosley

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 19

% Patents Active = 94.7

Average Co-Inventor Count = 3.8

ph-index = 13

Forward Citations = 568(Granted Patents)


Company Filing History:

goldMedal19 out of 451 
 
Immunex Corporation
 patents

Years Active: 1994-2008

Loading Chart...
Areas of Expertise:
Interleukin-4 Receptors
Type II IL-1 Receptors
Antibodies
DNA Encoding
Receptor Subunits
Oncostatin M
Biological Responses
Immunoreactive Antibodies
19 patents (USPTO):Explore Patents
1. 7317090 - Antibodies to Interleukin-4 receptors and uses thereof (2008-01-08),
2. 6716587 - Antibodies to interleukin-4 receptors and uses thereof (2004-04-06),
3. 6548655 - Interleukin-4 receptors (2003-04-15),
4. 6524817 - DNA encoding a receptor subunit for oncostatin M (2003-02-25),
5. 6521740 - Type II Interleukin-1 receptors (2003-02-18),
6. 6504023 - DNA encoding type II IL-1 receptors (2003-01-07),
7. 6391581 - DNA encoding interleukin-4 receptors (2002-05-21),
8. 6010886 - Receptor for oncostatin M (2000-01-04),
9. 5925740 - Antibodies to receptor for oncostatin M (1999-07-20),
10. 5891997 - Receptor for oncostatin M (1999-04-06),
11. 5856296 - DNA encoding interleukin-4 receptors (1999-01-05),
12. 5840869 - DNA encoding interleukin-4 receptors (1998-11-24),
13. 5783672 - Receptor for oncostatin M (1998-07-21),
14. 5767065 - Use of interleukin-4 receptors to inhibit biological responses mediated (1998-06-16),
15. 5767064 - Soluble type II interleukin-1 receptors and methods (1998-06-16),

Title: Innovations and Contributions of Bruce A. Mosley in Biotech

Introduction

Bruce A. Mosley, based in Seattle, WA, is a prominent inventor in the field of biotechnology, with a remarkable portfolio that includes 19 patents. His contributions primarily focus on antibodies and their applications in therapeutic modalities. His research has significantly impacted the understanding and treatment of immune-related conditions.

Latest Patents

Bruce A. Mosley holds several notable patents. Among his latest patents is one detailing "Antibodies to Interleukin-4 Receptors and Uses Thereof," which discloses methods and compositions related to antibodies that bind to mammalian interleukin-4 receptor proteins. Another significant patent also titled "Antibodies to Interleukin-4 Receptors and Uses Thereof" details mammalian interleukin-4 receptor proteins, DNAs, and expression vectors encoding these receptors, alongside processes for their production as products of cell culture. Additionally, he has developed a method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including humans, by administering an effective amount of soluble IL-4 receptor (sIL-4R) combined with a suitable diluent or carrier.

Career Highlights

Bruce A. Mosley has dedicated his career to advancing the field of immunology through his work at Immunex Corporation. His research has resulted in numerous patents that facilitate the understanding of immune receptor functions and therapeutic applications, positioning him as a key innovator within the organization.

Collaborations

Throughout his career, Bruce has collaborated with several esteemed colleagues, including David J. Cosman and Linda S. Park. These collaborations have undoubtedly enriched his research and led to significant advancements in the biotechnology field, contributing further to the potential of therapeutic antibodies.

Conclusion

In summary, Bruce A. Mosley is a pivotal figure in the realm of biotechnology, with a strong emphasis on antibodies and immune system responses. His 19 patents reflect his dedication to innovation and the enhancement of therapeutic strategies in combating immune-related disorders. With ongoing contributions through his work at Immunex Corporation, Bruce continues to shape the future of biotechnological advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…